Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.

Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, Wright K, Dueck AC, Jameson G, Von Hoff DD.

J Cancer. 2012;3:345-53. doi: 10.7150/jca.4714. Epub 2012 Aug 17.

PMID:
22962561
[PubMed]
Free PMC Article
2.

A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Venkatakrishnan K, Pickard MD, von Moltke LL.

Clin Pharmacokinet. 2010 Nov;49(11):703-27. doi: 10.2165/11536740-000000000-00000.

PMID:
20923246
[PubMed - indexed for MEDLINE]
3.

Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.

Filion M, Forget G, Brochu O, Provencher L, Desbiens C, Doyle C, Poirier B, DuRocher M, Camden S, Lemieux J.

Clin Trials. 2012 Oct;9(5):652-9. doi: 10.1177/1740774512456453.

PMID:
23060323
[PubMed - indexed for MEDLINE]
4.

Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.

Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C.

Ann Pharmacother. 2013 Mar;47(3):324-32. doi: 10.1345/aph.1R621. Epub 2013 Mar 12.

PMID:
23482734
[PubMed - indexed for MEDLINE]
5.

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.

Sproule BA, Naranjo CA, Brenmer KE, Hassan PC.

Clin Pharmacokinet. 1997 Dec;33(6):454-71. Review.

PMID:
9435993
[PubMed - indexed for MEDLINE]
6.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
[PubMed - indexed for MEDLINE]
8.

Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.

Penberthy L, Brown R, Wilson-Genderson M, Dahman B, Ginder G, Siminoff LA.

Clin Trials. 2012 Dec;9(6):788-97. doi: 10.1177/1740774512458992. Epub 2012 Oct 2.

PMID:
23033547
[PubMed - indexed for MEDLINE]
9.

Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia.

Ishak KJ, Tan Y, Glass J, Luong D, Caro JJ.

Clin Ther. 2008 Jul;30(7):1251-63.

PMID:
18691984
[PubMed - indexed for MEDLINE]
10.

Computer-based screening of patients with HIV/AIDS for clinical-trial eligibility.

Carlson RW, Tu SW, Lane NM, Lai TL, Kemper CA, Musen MA, Shortliffe EH.

Online J Curr Clin Trials. 1995 Mar 28;Doc No 179:[3347 words; 32 paragraphs].

PMID:
7719564
[PubMed - indexed for MEDLINE]
11.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
[PubMed - indexed for MEDLINE]
12.

Proton pump inhibitor discontinuation in long-term care.

Linsky A, Hermos JA, Lawler EV, Rudolph JL.

J Am Geriatr Soc. 2011 Sep;59(9):1658-64. doi: 10.1111/j.1532-5415.2011.03545.x. Epub 2011 Aug 24.

PMID:
21883102
[PubMed - indexed for MEDLINE]
13.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
14.

Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis.

Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M.

Clin Ther. 2011 Dec;33(12):1914-31. doi: 10.1016/j.clinthera.2011.10.019. Epub 2011 Nov 14.

PMID:
22088416
[PubMed - indexed for MEDLINE]
15.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
[PubMed - indexed for MEDLINE]
16.

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS.

J Clin Oncol. 2001 Mar 15;19(6):1728-33.

PMID:
11251003
[PubMed - indexed for MEDLINE]
17.

Impact of medication therapy discontinuation on mortality after myocardial infarction.

Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS.

Arch Intern Med. 2006 Sep 25;166(17):1842-7.

PMID:
17000940
[PubMed - indexed for MEDLINE]
18.

Antidepressants for smoking cessation.

Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T.

Cochrane Database Syst Rev. 2014 Jan 8;1:CD000031. doi: 10.1002/14651858.CD000031.pub4. Review.

PMID:
24402784
[PubMed - indexed for MEDLINE]
19.

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.

Hemeryck A, Belpaire FM.

Curr Drug Metab. 2002 Feb;3(1):13-37. Review.

PMID:
11876575
[PubMed - indexed for MEDLINE]
20.

Determinants of patient screen failures in Phase 1 clinical trials.

Mckane A, Sima C, Ramanathan RK, Jameson G, Mast C, White E, Fleck S, Downhour M, Von Hoff DD, Weiss GJ.

Invest New Drugs. 2013 Jun;31(3):774-9. doi: 10.1007/s10637-012-9894-7. Epub 2012 Nov 8.

PMID:
23135779
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk